Not Signed In -
Factor VIIa, Recombinant |
NovoSeven |
Clinical Trial: Dose Response to Recombinant Factor VIIa when administered for Bleed
This study is no longer recruiting patients.
|
Purpose
The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Healthy | Drug: NovoSeven, rFVIIa | Phase I |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Study start: June 2004; Study completion: February 2005
Last follow-up: November 2004; Data entry closure: December 2004
Eligibility
Ages Eligible for Study: 18 Years - 60 Years, Genders Eligible for Study: Male
Accepts Healthy Volunteers
Criteria
Ages Eligible for Study: 18 Years - 60 Years
Location Information
Kansas
Lenexa, Kansas, 66219, United States
More Information
Study ID Numbers: F7DRC-2157
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: February 28, 2005
ClinicalTrials.gov Identifier: NCT00104455
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: February 28, 2005
ClinicalTrials.gov Identifier: NCT00104455
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Factor VIIa, Recombinant (Drug Digest)
- NovoSeven (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
